Volume 10, Issue 1 (January 2008) 10, 14–22; 10.1111/j.1745-7262.2008.00362.x
Endothelium-specific gene and stem cell-based therapy for erectile dysfunction
Travis D Strong, Milena A Gebska, Arthur L Burnett, Hunter C Champion and Trinity J Bivalacqua
1.The Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287, USA 2.Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
Correspondence: Dr Trinity J Bivalacqua, The Brady Urological Institute, Department of Urology, Johns Hopkins Hospital, 600 N. Wolfe Ave., Marburg 143 Baltimore, MD 21287, USA. Fax: +1-410-614-3695. E-mail: tbivala1@jhmi.edu
Abstract |
Erectile dysfunction (ED) commonly results from endothelial dysfunction of the systemic vasculature. Although phosphodiesterase type 5 (PDE-5) inhibitors are effective at treating most cases of ED, they must be taken routinely and are ineffectual for a meaningful number of men. In recent years gene and stem cell-based therapies targeted at the penile endothelium have been gaining momentum in preclinical studies. These early studies reveal that gene and stem cell-based therapies may be both enduring and efficacious, and may eventually lead to a cure for ED. The following review will highlight our current understanding of endothelial-specific gene and stem cell-based therapies performed to date in a number of experimental animal models.
Keywords: erectile dysfunction, endothelial-specific gene, endothelial dysfunction, gene therapy
Full Text |
PDF |
中文摘要 |
|
|
Browse: 4280 |
|